News

Exploring Innovations in Cannabinoid Medicine at Avicanna's Symposium

Exploring Innovations in Cannabinoid Medicine at Avicanna's Symposium

Avicanna's 5th Medical Symposium on Cannabinoid Medicine

On June 6, a well-anticipated medical symposium will be hosted by Avicanna Inc., a prominent biopharmaceutical company dedicated to the innovative exploration of cannabinoid-based medicine. This exciting event, taking place at the MaRS Discovery District, aims to bring together healthcare practitioners and researchers to share knowledge and expand the understanding of cannabinoid treatments.

Event Highlights

The symposium, aptly titled "From Emerging Evidence to Clinical Practice," will delve into various topics surrounding cannabinoid medicine. Attendees can expect to hear from key opinion leaders and experts from both Canadian and international backgrounds. Highlighted speakers include renowned clinicians and scientists, who will present on the latest research and clinical practices.

Featured Speakers and Their Contributions

The quality of discussion at the symposium will be enhanced by presentations from a diverse group of experts:

  • Dr. Carrie Cuttler from Washington State University will explore the therapeutic potential of cannabigerol without inducing a high.
  • Dr. Jason McDougall from Dalhousie University will discuss the role of cannabinoids in managing arthritis.
  • Carlo De Angelis from Sunnybrook Health Sciences Centre will present unique patient cases showcasing innovative uses of medical cannabis.
  • Dr. Daniel Bear from Humber College will address considerations for medical cannabis education among healthcare professionals.
  • Dr. Zachary Walsh from the University of British Columbia will cover new findings on cannabis use among high-risk populations.
  • Dr. Kelly Dunn from Johns Hopkins School of Medicine will highlight evidence of interactions between opioids and cannabinoids.
  • Dr. Hance Clarke from University Health Network will showcase the Canadian Medical Cannabis Clinical Trials Network.
  • Dr. Jennifer Baumbusch from the University of British Columbia will present current research regarding cannabis use among older adults.
  • Dr. Evan Lewis from North Toronto Neurology will discuss advancements in cannabis-based therapies for epilepsy.

The Importance of Knowledge Exchange

According to Dr. Karolina Urban, Executive Vice President of Medical Affairs at Avicanna, this symposium builds on the previous year's success. It aims to enhance collective understanding and facilitate meaningful dialogue on cannabinoid-based medicines across the medical community. This platform signifies a pivotal opportunity for collaboration and education.

Abstract Submissions for Poster Presentations

The symposium also encourages researchers and practitioners to submit abstracts for a dedicated poster presentation session. This initiative emphasizes ongoing knowledge exchange and may serve as an avenue for advancing research in cannabinoid-based medicine.

How to Register

Healthcare practitioners and researchers interested in attending the symposium can register and submit abstracts for poster presentations through Avicanna's website.

About Avicanna

Avicanna Inc. (TSX: AVCN, OTCQX: AVCNF, Frankfurt: 0NN) is devoted to promoting the advancement and commercialization of plant-derived cannabinoid products. The company has successfully developed a range of proprietary products, backed by extensive research and clinical development.

  • RHO Phyto™ Medical Cannabis Formulary: Avicanna offers a wide spectrum of cannabinoid products including oral, sublingual, topical, and transdermal formulations, with a dedication to patient education.
  • MyMedi.ca: This platform enhances the medical cannabis journey for patients, offering bilingual support programs and educational resources.
  • Pharmaceutical Pipeline: Avicanna is advancing various clinical-stage cannabinoid candidates targeting dermatology, chronic pain, and neurological disorders.
  • Aureus Santa Marta™: The active pharmaceutical ingredients supplied by Santa Marta Golden Hemp SAS support the development of high-quality cannabinoid products for international partners.

Frequently Asked Questions

What is the main focus of Avicanna's fifth medical symposium?

The symposium is focused on cannabinoid-based medicine and aims to bring together healthcare practitioners and researchers to share the latest findings and clinical practices.

Who are some of the featured speakers at the event?

Featured speakers include Dr. Carrie Cuttler, Dr. Jason McDougall, Carlo De Angelis, and many other distinguished experts in the field of cannabinoid medicine.

How can one register for the symposium?

Interested individuals can register and submit abstracts for poster presentations through the Avicanna website.

What type of topics will be discussed at the symposium?

Topics will cover a wide range of issues related to the therapeutic benefits, clinical applications, and research emerging in the field of cannabinoid medicine.

What is Avicanna's mission?

Avicanna's mission is to advance cannabinoid-based products and formulations to enhance the quality of care in the global medical and pharmaceutical markets.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Zenas BioPharma Investors Urged to Join Class Action Lawsuit

Updated Category News Views 119

Overview of the Class Action Lawsuit Levi & Korsinsky, LLP is reaching out to investors in Zenas BioPharma, Inc. regarding a crucial class action lawsuit. This lawsuit may greatly impact those who have invested in Zenas BioPharma as it seeks to compensate individuals who have suffered losses due to alleged securities fraud. Understanding the Legal Landscape This class...

Continue Reading
Ayar Labs Raises $155 Million to Transform AI Infrastructure

Updated Category News Views 716

Ayar Labs Secures Significant Funding to Enhance AI Infrastructure Ayar Labs has recently secured $155 million in financing aimed at addressing the critical needs in AI infrastructure. With backing from prominent investors such as AMD Ventures, Intel Capital, and NVIDIA, alongside Advent Global Opportunities and Light Street Capital, this investment elevates the total...

Continue Reading
Transforming the Non-Profit Sector: The Impact Collaborative

Updated Category News Views 159

Impact Collaborative Launches to Transform the Non-Profit Sector Today marks a significant milestone with the launch of the Impact Collaborative (IC), a pioneering initiative aimed at revolutionizing the support provided to under-resourced communities. This innovative approach seeks to disrupt generational poverty while offering much-needed access to mental health and...

Continue Reading
Synovus Financial Corp Declares Quarterly Dividends for Investors

Updated Category News Views 128

Synovus Financial Corp Declares Quarterly Dividends Synovus Financial Corp. (NYSE: SNV) has recently revealed the details of its latest quarterly dividends. The board of directors has approved significant payouts to its shareholders, reinforcing the company’s ongoing commitment to deliver value to its investors. Details of the Declared Dividends The following dividends...

Continue Reading
Walnut Hill Medical Enhances Patient Access Through FDA TAP Program

Updated Category News Views 171

Walnut Hill Medical Partners with FDA in TAP Program Walnut Hill Medical, a prominent healthcare consultancy known for its market access and reimbursement strategies, has been chosen as an advisor to the FDA's Total Product Life Cycle Advisory Program (TAP). This initiative, which originated from the FDA's Center for Devices and Radiological Health (CDRH), aims to improve...

Continue Reading